Tesaro (TSRO) Valuation Range Lifted to $122-$132 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
TESARO (TSRO) Phase 3 Niraparib Results a 'Grand Slam' - Mizuho
June 29, 2016 9:01 AM EDTMizuho Securities analyst Eric Criscuolo weighed in on Tesaro (NASDAQ: TSRO), calling results from the Phase III NOVA trial a "grand slam."
Criscuolo commented, "The trial met its primary endpoints in all three ovarian cancer patient cohorts: germline BRCA-mutant, non-germline but HRD... More
Credit Suisse Sees $157B of FCF Through 2019 Available for M&A in Biotech/Pharma Sector
June 29, 2016 7:56 AM EDTAnalysts at Credit Suisse evaluated potential M&A in the biotech sector beyond Medivation (NASDAQ: MDVN), which in addition to a hostile bid from Sanofi (NYSE: SNY) has been looked at by multiple firms.
Analysts led by Vamil Divan said... More
TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:02 AM EDTTESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice® HRD test, and overall in patients who are not germline BRCA mutation carriers.
We are extremely grateful to the patients, caregivers, and investigators who participated in... More
